摘要
目的:探讨依西美坦治疗绝经后乳腺癌的疗效及安全性进行观察。方法:观察84名病理明确证实绝经后乳腺癌且雌激素受体(ER)或孕激素受体(PgR)阳性患者,口服依西美坦25 mg/d,服药至病情进展或出现不能耐受的不良反应,观察依西美坦的疗效和不良反应。结果:84例患者均可评价疗效,客观有效率为(23/84)27.4%;疾病控制率为(34/84)41%;并且绝经的方式,前期化疗,手术与否与疗效的关系无明显统计学差异,但转移部位,前期内分泌治疗史可能对疗效有影响;依西美坦治疗后不良反应发生率低。结论:依西美坦对乳腺癌的疗效确切,且不良反应轻,耐受性好。
Objective： To investigate exemestane efficacy and safety in the treatment of postmenopausal breast cancer.Methods： 84 patients with post-menopausal breast cancer who had estrogen receptor（ER） or progesterone receptor（PgR） positive were enrolled into the study.The regimen was oral intake of exemestane 25 mg once daily until the disease progression or intolerable toxic reaction occurred.In the process,the therapeutic effect and toxic effect were observed.Results： 84 patients are enough to evaluate the therapeutic effect.Among the 84 patients,the total response rate was（23/84） 27.4 % and the disease control rate was（34/84） 41 %.Therapeutic effect has no relationship among different ways of postmenopausal,previous chemotherapy,and surgery.But the Sites of metastatic,the endocrine therapy influences on the therapeutic effect.Conclusion： Exemestane was effective and safe for patients with a post-menopausal breast cancer who had ER or PgR positive.Furthermore,exemestane has a good tolerance,and the adverse reaction is light.
出处
《现代生物医学进展》
CAS
2013年第12期2332-2334,2324,共4页
Progress in Modern Biomedicine
关键词
依西美坦
绝经后
乳腺癌
Exemestane
Post-menopausal
Breast Cancer
